Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.8
4.4
Journals
Cancers
Special Issues
Advances in the Management of Prostate Cancer: New Insights into...
share announcement

Advances in the Management of Prostate Cancer: New Insights into Biological and Clinical Factors

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 August 2025 | Viewed by 3843

Special Issue Editors

Dr. Mutlay Sayan

E-Mail Website
Guest Editor
Department of Radiation Oncology, Brigham and Women’s Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Interests: genitourinary malignancies; prostate cancer; radiation oncology
Dr. Yetkin Tuac

E-Mail Website
Guest Editor
Department of Statistics, Ankara University, 06100 Ankara, Türkiye
Interests: big data; biostatistics; computer science; statistical analysis and applications

Special Issue Information

Dear Colleagues,

Prostate cancer remains a major global health concern, with ongoing developments enhancing our understanding of its biological mechanisms and clinical management. This Special Issue aims to explore the latest advancements in the management of prostate cancer, highlighting innovative diagnostic tools, risk stratification models and tailored therapeutic strategies, such as androgen receptor signaling inhibitors, targeted therapies and innovations in surgical and radiation therapy.

We invite submissions of original research articles and comprehensive reviews that provide new insights into these areas. This Special Issue intends to foster interdisciplinary collaboration and serve as a vital resource for researchers, clinicians and healthcare professionals dedicated to enhancing patient outcomes through integrated scientific discovery and clinical application.

We look forward to your contributions and advancing our collective understanding and management of prostate cancer.

Dr. Mutlay Sayan
Dr. Yetkin Tuac
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • prostate cancer
  • risk stratification
  • genomic alterations
  • radiation therapy
  • prostatectomy
  • androgen deprivation therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

11 pages, 399 KiB  
Article
Multiple or More Severe Grade Prevalent Vertebral Fractures Are Associated with Higher All-Cause Mortality in Men with Nonmetastatic Prostate Cancer Receiving Androgen Deprivation Therapy
by Kashia Goto, Daisuke Watanabe, Hiromitsu Takano, Kazuki Yanagida, Norikazu Kawae, Hajime Kajihara and Akio Mizushima
Cancers 2025, 17(13), 2131; https://doi.org/10.3390/cancers17132131 - 25 Jun 2025
Viewed by 318
Abstract
Background/Objectives: Prognostic information for nonmetastatic prostate cancer (nmPC) patients with prevalent vertebral fractures (PVFs) is very limited. Vertebral fractures can impair physical function, limit activities of daily living, and decrease quality of life. Prevention of vertebral fractures may be important to improve [...] Read more.
Background/Objectives: Prognostic information for nonmetastatic prostate cancer (nmPC) patients with prevalent vertebral fractures (PVFs) is very limited. Vertebral fractures can impair physical function, limit activities of daily living, and decrease quality of life. Prevention of vertebral fractures may be important to improve patient prognosis. This study aims to investigate the impact of the presence and severity of PVFs on overall survival in patients with nmPC undergoing androgen deprivation therapy (ADT). Methods: A total of 275 men (median age: 73 years) with nmPC who underwent ADT were studied retrospectively. The median observation period was 55 months. Variables included age, body mass index, T classification, N classification, Gleason score, and pretreatment serum prostate-specific antigen levels. PVF was diagnosed from the sagittal computed tomography images of Th1 to L5 before initiating ADT, and the severity was determined by the number of PVFs and the Semiquantitative (SQ) method. Hazard ratios and 95% confidence intervals for overall survival were calculated using the Cox proportional hazards model. Results: During the observation period, 30 patients died from all causes. Multivariate Cox regression analysis identified multiple PVFs and high-grade PVFs, as determined by the SQ method, as significant predictors of overall survival. The analysis utilized two adjustment models: one adjusted for age only and the other adjusted for age, Gleason score, and clinical T stage. Conclusions: Multiple PVFs and high-grade PVF determined by the SQ method prior to ADT initiation were associated with higher all-cause mortality in nmPC patients treated with ADT. Full article
(This article belongs to the Special Issue Advances in the Management of Prostate Cancer: New Insights into Biological and Clinical Factors)
►▼ Show Figures

Figure 1

Other

Jump to: Research

26 pages, 1485 KiB  
Systematic Review
Early Versus Delayed Androgen Deprivation Therapy for Biochemical Recurrence After Local Curative Treatment in Non-Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review of the Literature
by Muneeb Uddin Karim, Steven Tisseverasinghe, Rodrigo Cartes, Constanza Martinez, Boris Bahoric and Tamim Niazi
Cancers 2025, 17(2), 215; https://doi.org/10.3390/cancers17020215 - 10 Jan 2025
Viewed by 2998
Abstract
Background: The ideal timing of androgen deprivation therapy (ADT) for patients with biochemical recurrence (BCR) of prostate cancer (PCa) remains controversial due to its side effects and uncertain impact on survival outcomes. Methods: We performed a review of the current literature by comprehensively [...] Read more.
Background: The ideal timing of androgen deprivation therapy (ADT) for patients with biochemical recurrence (BCR) of prostate cancer (PCa) remains controversial due to its side effects and uncertain impact on survival outcomes. Methods: We performed a review of the current literature by comprehensively searching the PubMed, Embase, and Cochrane databases to determine the optimal timing of ADT initiation after biochemical recurrence. We selected 26 studies including systematic reviews, randomized controlled trials (RCTs), and retrospective studies, while also reviewing practice guidelines. Results: Not all patients with BCR cancer experience clinical or radiological progression. While early ADT may delay progression, evidence of its effect on PCa-specific mortality remains inconclusive. The PSA thresholds for initiating ADT vary, complicating decision-making. Key predictors of progression include a short PSA doubling time (PSADT), a high Gleason score (GS), and a brief interval to BCR of PCa post-radiotherapy (RT). Combining ADT with androgen receptor pathway inhibitors (ARPIs) has been shown to improve metastasis-free survival in high-risk patients. Conclusion: The ideal timing of ADT initiation in BCR PCa remains uncertain. Early ADT can help control the progression, but its effect on PCa-specific mortality is unclear. Stratifying patients by their risk factors, such as their PSADT, GS, and time to BCR can guide individualized treatment. In high-risk patients, delaying ADT should be avoided, while combining ADT with an androgen receptor pathway inhibitor (ARPI) may further improve outcomes. Full article
(This article belongs to the Special Issue Advances in the Management of Prostate Cancer: New Insights into Biological and Clinical Factors)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop